title: Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction.
abstract: As statins are recommended at discharge to all patients following myocardial infarction (MI), we studied their use and efficacy in renal disease by analyzing the data, in the nationwide SWEDEHEART registry, of 42,814 consecutive survivors of MI with available creatinine/dialysis data but without statin therapy on admission. The estimated glomerular filtration rate (eGFR) was determined by the Modification of Diet in Renal Disease Study formula and the patients classified into the five traditional stages of kidney disease. The 1-year survival in relation to prescription of statin at discharge was assessed in a Cox regression analysis adjusted by a propensity score that described each individual's likelihood of being treated with a statin, established by 36 baseline characteristics and in-hospital therapies. Statin use at discharge decreased with increased renal impairment from 81% in eGFR stage 1 to 31% in eGFR stage 5. After adjusting for the propensity score and discharge medication, statin use was associated with a significant reduction in overall risk of death (hazard ratio 0.63), with a statistically significant interaction between statin therapy and the stage of renal function. Thus, statin use at discharge was associated with improved 1-year survival of patients in stages 2-4 (mild-to-severe) of renal insufficiency. This effect appears attenuated in those with stage 5 renal failure.
authors.affiliation: Department of Medicine, Section of Cardiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. karolina.szummer@karolinska.se
authors.forename: Karolina
authors.initials: K
authors.lastname: Szummer
authors.forename: Pia
authors.initials: P
authors.lastname: Lundman
authors.forename: Stefan H
authors.initials: SH
authors.lastname: Jacobson
authors.forename: Staffan
authors.initials: S
authors.lastname: Schön
authors.forename: Johan
authors.initials: J
authors.lastname: Lindbäck
authors.forename: Ulf
authors.initials: U
authors.lastname: Stenestrand
authors.forename: Lars
authors.initials: L
authors.lastname: Wallentin
authors.forename: Tomas
authors.initials: T
authors.lastname: Jernberg
mesh_terms: D000328:Adult; D000368:Aged; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology*; D006435:Renal Dialysis; D017741:Survivors; D016896:Treatment Outcome
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors